FDA Revisits Botanical Drug Approvals Amid Ongoing Therapeutic Challenges
The FDA is re-examining its stance on botanical medicines while highlighting persistent obstacles to clozapine use and the potential of pig kidneys for human transplants.
Why it matters
Regulatory shifts and new transplant approaches could affect future treatment options and biotech investment.
In this story
FDAbotanical drugsclozapinepig kidneysbiotechdrug approvaltransplant research
